在体外单独暴露于替诺福韦或与阿巴卡韦或拉米夫定联合使用时，1型人类免疫缺陷病毒逆转录酶的突变选择。
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
作者信息
Stone Chris, Ait-Khaled Mounir, Craig Charles, Griffin Philip, Tisdale Margaret
机构信息
International Clinical Virology, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire SG1 2NY, United Kingdom.
出版信息
Antimicrob Agents Chemother. 2004 Apr;48(4):1413-5. doi: 10.1128/AAC.48.4.1413-1415.2004.
Abstract
Mutations selected or deselected during passage of human immunodeficiency virus strain HXB2 or resistant variants with tenofovir (TFV), abacavir (ABC), and lamivudine (3TC) differed depending on the drug combination and virus genotype. In the wild-type virus, TFV-ABC and TFV-3TC selected K65R (with reduced susceptibility to all three inhibitors) and then Y115F. TFV-containing regimens might increase K65R selection, which confers multiple nucleoside reverse transcriptase inhibitor resistance.
摘要
在人类免疫缺陷病毒1型（HIV-1）HXB2毒株或对替诺福韦（TFV）、阿巴卡韦（ABC）和拉米夫定（3TC）耐药的变异株传代过程中选择或未选择的突变，因药物组合和病毒基因型而异。在野生型病毒中，TFV-ABC和TFV-3TC选择了K65R（对所有三种抑制剂的敏感性降低），然后是Y115F。含TFV的治疗方案可能会增加K65R的选择，这会导致对多种核苷类逆转录酶抑制剂耐药。
相似文献
1
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.在体外单独暴露于替诺福韦或与阿巴卡韦或拉米夫定联合使用时，1型人类免疫缺陷病毒逆转录酶的突变选择。
Antimicrob Agents Chemother. 2004 Apr;48(4):1413-5. doi: 10.1128/AAC.48.4.1413-1415.2004.
2
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.初治患者中HIV-1逆转录酶K65R突变的流行情况及决定因素
AIDS. 2002 Oct 18;16(15):2087-9. doi: 10.1097/00002030-200210180-00018.
3
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.使用替诺福韦与恩曲他滨组合或阿巴卡韦与拉米夫定组合进行1型人类免疫缺陷病毒的体外耐药性筛选。
Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. doi: 10.1128/AAC.00816-06. Epub 2006 Sep 18.
4
Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.霉酚酸对HIV-1复制的剂量依赖性抑制以及与阿巴卡韦、去羟肌苷和替诺福韦联合使用时的协同抑制作用。
Antiviral Res. 2002 Jul;55(1):41-52. doi: 10.1016/s0166-3542(02)00006-2.
5
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.人类免疫缺陷病毒1型逆转录酶中的K70E突变赋予对核苷类逆转录酶抑制剂耐药性的分子机制。
Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. doi: 10.1128/AAC.00683-06. Epub 2006 Nov 6.
6
Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.替诺福韦、阿巴卡韦和拉米夫定之间不存在代谢及抗病毒药物相互作用。
Antivir Ther. 2005;10(3):451-7.
7
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.即使在拉米夫定存在的情况下，替诺福韦也能选择出猿猴免疫缺陷病毒逆转录酶中M184V突变的回复突变。
J Virol. 2003 Jan;77(2):1120-30. doi: 10.1128/jvi.77.2.1120-1130.2003.
8
Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.HIV逆转录酶中W153L替换对病毒复制及对多类逆转录酶抑制剂耐药性的影响。
Antimicrob Agents Chemother. 2014 Aug;58(8):4515-26. doi: 10.1128/AAC.02729-14. Epub 2014 May 27.
9
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.齐多夫定、拉米夫定和替诺福韦治疗失败后HIV-1的克隆耐药性分析
Antivir Ther. 2010;15(3):437-41. doi: 10.3851/IMP1539.
10
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.1型人类免疫缺陷病毒逆转录酶导致替诺福韦耐药的分子机制，该逆转录酶在69位残基后含有双丝氨酸插入及多个与胸苷类似物相关的突变。
Antimicrob Agents Chemother. 2004 Mar;48(3):992-1003. doi: 10.1128/AAC.48.3.992-1003.2004.
引用本文的文献
1
Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments.抗逆转录病毒体外传代实验中选择的 HIV 突变综合数据库。
Antiviral Res. 2024 Oct;230:105988. doi: 10.1016/j.antiviral.2024.105988. Epub 2024 Aug 16.
2
Avoiding Drug Resistance in HIV Reverse Transcriptase.避免 HIV 逆转录酶的耐药性。
Chem Rev. 2021 Mar 24;121(6):3271-3296. doi: 10.1021/acs.chemrev.0c00967. Epub 2021 Jan 28.
3
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.接受世界卫生组织推荐的含替诺福韦一线方案的个体中病毒学失败的突变相关性：一项国际合作。
EBioMedicine. 2017 Apr;18:225-235. doi: 10.1016/j.ebiom.2017.03.024. Epub 2017 Mar 19.
4
Physiological Mg Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.生理镁离子条件在体外显著改变核苷类和非核苷类抑制剂对HIV-1和HIV-2逆转录酶的抑制作用。
Biochemistry. 2017 Jan 10;56(1):33-46. doi: 10.1021/acs.biochem.6b00943. Epub 2016 Dec 27.
5
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.一种多药耐药的HIV-1 A/G亚型逆转录酶的生化特性：齐多夫定识别与切除途径的拮抗作用以及对核糖核酸酶H抑制剂的敏感性
Nucleic Acids Res. 2016 Mar 18;44(5):2310-22. doi: 10.1093/nar/gkw060. Epub 2016 Feb 4.
6
High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.在南非，接受基于替诺福韦的一线治疗方案失败的HIV-1 C亚型感染患者中，K65R突变的高流行率。
PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.
7
The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.HIV-1逆转录酶中赖氨酸65残基的功能及核苷类似物耐药性
Viruses. 2014 Oct 23;6(10):4080-94. doi: 10.3390/v6104080.
8
Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.HIV-1逆转录酶中的突变会影响病毒复制单个周期中产生的错误。
J Virol. 2014 Jul;88(13):7589-601. doi: 10.1128/JVI.00302-14. Epub 2014 Apr 23.
9
Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia.在柬埔寨，使用包含司他夫定的一线抗逆转录病毒治疗失败的患者中，Q151M 和 K65R 突变的风险增加。
PLoS One. 2013 Aug 28;8(8):e73744. doi: 10.1371/journal.pone.0073744. eCollection 2013.
10
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.核苷逆转录酶抑制剂（NRTI）BMS-986001 对已知 NRTI 耐药突变的体外交叉耐药谱。
Antimicrob Agents Chemother. 2013 Nov;57(11):5500-8. doi: 10.1128/AAC.01195-13. Epub 2013 Aug 26.
本文引用的文献
1
Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.阿巴卡韦对接受过抗逆转录病毒治疗、感染具有特定核苷类逆转录酶抑制剂耐药模式的HIV-1的成年患者的抗病毒疗效。
Antivir Ther. 2004 Feb;9(1):37-45. doi: 10.1177/135965350400900102.
2
Drug resistance mutations in HIV-1.HIV-1中的耐药性突变
Top HIV Med. 2003 May-Jun;11(3):92-6.
3
Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.即使在拉米夫定存在的情况下，替诺福韦也能选择出猿猴免疫缺陷病毒逆转录酶中M184V突变的回复突变。
J Virol. 2003 Jan;77(2):1120-30. doi: 10.1128/jvi.77.2.1120-1130.2003.
4
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.具有逆转录酶突变K65R和K65R+M184V的1型人类免疫缺陷病毒耐药性的分子机制及其对酶功能和病毒复制能力的影响。
Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46. doi: 10.1128/AAC.46.11.3437-3446.2002.
5
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
AIDS. 2002 Aug 16;16(12):1686-9. doi: 10.1097/00002030-200208160-00017.
6
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.使用替诺福韦酯治疗的有抗逆转录病毒治疗经验的患者中HIV-1的基因型和表型分析。
AIDS. 2002 Jun 14;16(9):1227-35. doi: 10.1097/00002030-200206140-00004.
7
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.在人免疫缺陷病毒1型逆转录酶中进行体外突变筛选，这些突变可降低对（-）-β-D-二氧戊环鸟苷的敏感性并抑制对3'-叠氮基-3'-脱氧胸苷的耐药性。
Antimicrob Agents Chemother. 2000 Jul;44(7):1783-8. doi: 10.1128/AAC.44.7.1783-1788.2000.
8
The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.阿巴卡韦（ABC，1592）在接受过抗逆转录病毒治疗的患者中的作用：一项随机、双盲试验的结果。CNA3002欧洲研究团队。
AIDS. 2000 May 5;14(7):781-9. doi: 10.1097/00002030-200005050-00003.
9
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.人类免疫缺陷病毒1型逆转录酶抑制剂阿巴卡韦（1592U89）单药治疗和联合治疗后的耐药情况。CNA2001研究小组。
J Infect Dis. 2000 Mar;181(3):912-20. doi: 10.1086/315317.
10
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.阿巴卡韦单药治疗及联合治疗期间HIV-1逆转录酶（RT）基因型与对RT抑制剂的敏感性
AIDS. 2000 Jan 28;14(2):163-71. doi: 10.1097/00002030-200001280-00012.
Zotero 插件